Latest from City of Hope

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.
Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.
Tanya Siddiqi, MD, discusses the results of the TRANSCEND CLL 004 trial.
 
Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.
David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.
Amir Khan, MD, discusses trends in the overall incidence of gastric cancer and colorectal cancer.
Amir Khan, MD, discusses the rising incidence of gastric and colorectal cancers in young adult patients.
 
After more than 30 years of leadership as chair of City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, Stephen J. Forman, MD, has decided to transition out of this role.
Publication Bottom Border
Border Publication
x